X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs ALEMBIC PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA ALEMBIC PHARMA ABBOTT INDIA/
ALEMBIC PHARMA
 
P/E (TTM) x 32.8 26.6 123.4% View Chart
P/BV x 8.2 6.1 135.1% View Chart
Dividend Yield % 0.8 0.8 105.5%  

Financials

 ABBOTT INDIA   ALEMBIC PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
ALEMBIC PHARMA
Mar-16
ABBOTT INDIA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs6,015792 759.8%   
Low Rs3,707443 836.8%   
Sales per share (Unadj.) Rs1,236.9167.0 740.6%  
Earnings per share (Unadj.) Rs122.238.2 320.2%  
Cash flow per share (Unadj.) Rs129.042.0 307.1%  
Dividends per share (Unadj.) Rs35.004.00 875.0%  
Dividend yield (eoy) %0.70.6 111.1%  
Book value per share (Unadj.) Rs521.284.9 613.9%  
Shares outstanding (eoy) m21.25188.52 11.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.93.7 106.3%   
Avg P/E ratio x39.816.2 245.9%  
P/CF ratio (eoy) x37.714.7 256.4%  
Price / Book Value ratio x9.37.3 128.3%  
Dividend payout %28.610.5 273.3%   
Avg Mkt Cap Rs m103,296116,383 88.8%   
No. of employees `0003.0NA-   
Total wages/salary Rs m3,3704,214 80.0%   
Avg. sales/employee Rs Th8,891.8NM-  
Avg. wages/employee Rs Th1,140.0NM-  
Avg. net profit/employee Rs Th878.3NM-  
INCOME DATA
Net Sales Rs m26,28431,487 83.5%  
Other income Rs m50455 915.4%   
Total revenues Rs m26,78931,542 84.9%   
Gross profit Rs m3,66510,060 36.4%  
Depreciation Rs m144722 20.0%   
Interest Rs m837 22.0%   
Profit before tax Rs m4,0179,356 42.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4212,160 65.8%   
Profit after tax Rs m2,5967,194 36.1%  
Gross profit margin %13.931.9 43.6%  
Effective tax rate %35.423.1 153.2%   
Net profit margin %9.922.8 43.2%  
BALANCE SHEET DATA
Current assets Rs m14,44615,066 95.9%   
Current liabilities Rs m4,7257,674 61.6%   
Net working cap to sales %37.023.5 157.6%  
Current ratio x3.12.0 155.7%  
Inventory Days Days5167 76.8%  
Debtors Days Days2041 48.1%  
Net fixed assets Rs m1,1138,237 13.5%   
Share capital Rs m213377 56.4%   
"Free" reserves Rs m10,80815,416 70.1%   
Net worth Rs m11,07616,005 69.2%   
Long term debt Rs m00-   
Total assets Rs m16,24124,594 66.0%  
Interest coverage x497.0255.2 194.7%   
Debt to equity ratio x00-  
Sales to assets ratio x1.61.3 126.4%   
Return on assets %16.029.4 54.5%  
Return on equity %23.444.9 52.1%  
Return on capital %36.358.7 61.9%  
Exports to sales %0.655.7 1.1%   
Imports to sales %12.610.4 121.2%   
Exports (fob) Rs m16217,551 0.9%   
Imports (cif) Rs m3,3223,283 101.2%   
Fx inflow Rs m26817,811 1.5%   
Fx outflow Rs m3,9275,318 73.9%   
Net fx Rs m-3,65912,493 -29.3%   
CASH FLOW
From Operations Rs m2,5149,304 27.0%  
From Investments Rs m-800-3,105 25.8%  
From Financial Activity Rs m-803-1,959 41.0%  
Net Cashflow Rs m9124,240 21.5%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 2.9 272.4%  
FIIs % 0.1 9.1 1.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 13.9 123.0%  
Shareholders   18,270 49,328 37.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  TORRENT PHARMA  STRIDES SHASUN LTD  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Aug 18, 2017 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - PLETHICO PHARMA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS